The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Abstract
Impaired cognitive functioning is often associated with major depressive disorder (MDD). Moreover, a number of agents used to treat MDD are known to have negative effects on cognitive functioning. We report an assessment of the effects of the selective norepinephrine reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor paroxetine, and placebo on a variety of measures of cognitive functioning in patients with MDD. Cognitive functioning in 74 adult patients (aged 18-65 years) with a confirmed diagnosis of MDD (DSM-IV) was assessed as part of two identical, randomized, double-blind, placebo- and active-treatment-controlled, fixed/flexible dose comparisons of 8 weeks of treatment with reboxetine (8-10 mg/day), paroxetine (20-40 mg/day) and placebo. Cognitive function was assessed at baseline, day 14 and day 56 using a selection of tasks from the Cognitive Drug Research computerized assessment system, including Simple Reaction Time, Digit Vigilance, Choice Reaction Time, Numeric Working Memory, Word Recognition and Critical Flicker Frequency. The results in the 74 patients (reboxetine n = 25, paroxetine n = 23, placebo n = 26) showed that reboxetine significantly improved the ability to sustain attention at day 56 compared with baseline (P = 0.023). In addition, patients who received reboxetine experienced significant improvements in their speed of cognitive functioning when tested at day 56 compared to baseline (P = 0.024). No significant changes or trends in this direction were seen among patients who received either placebo or paroxetine. The results of the present study provide objective data to support the possibility that reboxetine favourably affects cognitive processes in depressed patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies of the pharmacotherapy for cognitive or executive dysfunction in MDD have reported somewhat inconsistent findings (DeBattista, 2005;Ferguson et al, 2003;Herrera-Guzman et al, 2010).”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Ferguson et al, 2003
Citations
Cites
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492 · cited 1×
“There has been speculation in the medical research literature for over 30 years about the role of catecholamines in cognition and depression (Schildkraut, 1965; Crow, 1968; Mason and Iverson, 1977; Friedman et al., 1999; Ressler and Nemeroff, 1999).”
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Self-citationCognitive deficits in depression: Possible implications for functional neuropathology
Austin, M.-P., Mitchell, P., & Goodwin, G. M. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.200 · Cited by 1,154 · cited 1×
“Although difficulty in thinking has traditionally been considered to accompany depression, there is considerable disagreement in the literature as to which aspects of cognition are impaired by this disorder (Austin et al., 2001).”
Bosc, M., Dubini, A., & Polin, V. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00420-3 · Cited by 373 · cited 2×
“Using psychometric scales, such as the Social Adaptation Self-evaluation Scale (Bosc et al., 1997), reboxetine has been shown to rapidly restore patients’ social functioning capacity (Dubini et al., 1997a, b) which, in some cases, may occur before the resolution of their depressive symptoms.”
Effectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorder
Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J., Harding, M., Faraone, S. V., & Seidman, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.693 · Cited by 335 · cited 1×
“More recently, the norepinephrine reuptake inhibitor, tomoxetine, has been reported to be efficacious in the treatment of patients with ADHD, further suggesting a role for norepinephrine in attention and possibly other areas of cognitive functioning (Spencer et al., 1998).”
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor
Wong, E. H. F., Sonders, M. S., Amara, S. G., Tinholt, P. M., Piercey, M. F. P., Hoffmann, W. P., Hyslop, D. K., Franklin, S., Porsolt, R. D., Bonsignori, A., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00291-7 · Cited by 334 · cited 2×
“Wesnes and coworkers (Wesnes et al., 1994, 1997) demonstrated that trazodone and the tricyclic antidepressants (TCAs) amitriptyline and nortriptyline cause decrements in cognitive functioning in depressed patients and normal volunteers.”
Role of norepinephrine in the pathophysiology and treatment of mood disorders
Ressler, K. J., & Nemeroff, C. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00127-4 · Cited by 307 · cited 3×
“…and methylphenidate, in normal adults, children with attention deficit–hyperactivity disorder (ADHD), and elderly patients are suggestive of a role for norepinephrine and/or dopamine in attention, cognition, and memory (Birnbaum et al., 1999; Friedman et al., 1999; Ressler and Nemeroff, 1999).”
Wesnes, K. A., Ward, T., McGinty, A., & Petrini, O. (2000) · Psychopharmacology · doi:10.1007/s002130000533 · Cited by 304 · cited 2×
“Other antidepressants, such as the monoamine oxidase inhibitor moclobemide and sibutramine, appear to improve cognitive functioning in both normal volunteers and depressed patients (Wesnes et al., 1989, 2000a).”
Self-citationBirnbaum, S., Gobeske, K. T., Auerbach, J., Taylor, J. R., & Arnsten, A. F. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00138-9 · Cited by 281 · cited 2×
“…and methylphenidate, in normal adults, children with attention deficit–hyperactivity disorder (ADHD), and elderly patients are suggestive of a role for norepinephrine and/or dopamine in attention, cognition, and memory (Birnbaum et al., 1999; Friedman et al., 1999; Ressler and Nemeroff, 1999).”
Effects of selective forebrain noradrenaline loss on behavioral inhibition in the rat.
Mason, S. T., & Iversen, S. D. (1977) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0077311 · Cited by 214 · cited 1×
“There has been speculation in the medical research literature for over 30 years about the role of catecholamines in cognition and depression (Schildkraut, 1965; Crow, 1968; Mason and Iverson, 1977; Friedman et al., 1999; Ressler and Nemeroff, 1999).”
Research works printed but not linked: 8
- Dubini, 1997b, J Psychopharmacol, 11, S17???S23
- Friedman, 1999, Biol Psychiatry, 46, 1243???1252
- Kleinbloesem, 1996, Clin Pharmocol Ther, 59, 675???685
- Montgomery, 1997, J Psychopharmacol, 11, S9???S15
- O??Neill, 1995, Eur J Clin Pharmacol, 48, 447???453
- Wesnes, 1989, Br J Clin Pharmacol, 27, 647???648
- Wesnes, 1997, Br J Surgery, 84, 493???495, 10.1002/bjs.1800840416 · doi:10.1002/bjs.1800840416
- Wesnes, 1996, J Psychopharmacol, 10, A51
Cited by
Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 588
Lam, R. W., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901206 · Cited by 438
Rosenblat, J. D., Kakar, R., & McIntyre, R. S. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv082 · Cited by 315
“Pooled Effect Sizes for Placebo-Controlled Trials Effect on Psychomotor Speed (DSST or Combined Speed) In total, nine placebo-controlled studies evaluated psychomotor speed using DSST or a combined speed measure (Georgotas et al., 1989; Ferguson et al., 2003; Raskin et al., 2007; Hoffman et al., 2008; Culang et al., 2…”
BackgroundMethodBennabi, D., Vandel, P., Papaxanthis, C., Pozzo, T., & Haffen, E. (2013) · BioMed Research International · doi:10.1155/2013/158746 · Cited by 243
“combined the data of 4 clinical studies and found a significant improvement of PMR in patients following 4 weeks of reboxetine treatment [96].”
BackgroundEtiology of the post-concussion syndrome: Physiogenesis and psychogenesis revisited
Silverberg, N. D., & Iverson, G. L. (2011) · NeuroRehabilitation · doi:10.3233/nre-2011-0708 · Cited by 230
“If adequately treated, then some people with depression can experience a substantial improvement in their cognitive functioning [27,34,51].”
Background
Metadata
- Authors
- Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E.
- Affiliations
- University of Utah (US)
- Columbia University (US)
- Corresponding author
- Ferguson, James M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2003-01
- Volume
- 18
- Issue
- 1
- Pages
- 9-14
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1982842917
- Cited by
- 112
- References
- 21
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 13 · 2015: 5 · 2014: 10 · 2013: 10 · 2012: 3
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- reboxetine, paroxetine, major depressive disorder, cognitive function, attention, reaction time, working memory, norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, antidepressant side effects, cognitive impairment in depression
- MeSH terms
- Reboxetine, Adolescent, Adult, Aged, Antidepressive Agents, Cognition Disorders, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Placebos, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. https://app.cochat.ai/papers/10.1097/00004850-200301000-00002
- The paper
- Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003). Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200301000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.